Fertility experts urge the creation of registries to safeguard donor conception practices
SINGAPORE, May 2, 2025 /PRNewswire/ -- Gamete donation has accelerated around the world in the past decade driven in part by the emergence of commercial sperm and egg banks and a growing recognition of the validity of this form of family building among single women in some countries.
However, lack of regulation on donor conception in many countries is exposing those seeking to build families in this way to potential medical, legal and psychosocial ramifications.
Associate Professor Sonja Goedeke, a New Zealand-based clinical psychologist specialising in psychosocial and ethical implications of infertility, has called on policy makers to help those seeking donor conception to make safer choices for themselves, their donors and their potential offspring and families.
Speaking at the 2025 Congress of the Asia Pacific Initiative on Reproduction (ASPIRE) in Singapore, Associate Professor Goedeke said legislation, policies and practices regarding donor conception vary significantly across jurisdictions and anonymous donation remains possible in some countries, including across the Asia Pacific.
"Anonymity can prevent donor conceived people from accessing vital health information and deny them knowledge of their genetic origins," she said. "It may also increase the risk of half-siblings unknowingly forming relationships with each other.
"Internationally, many donor conceived people have emphasised their desire for and right to access information about the donor."
Associate Professor Goedeke said limited local access to egg, sperm and embryo donors may be one of the key drivers in so-called cross-border reproduction. "However, this may present significant risks including unspecified donor limits leading to potentially large numbers of siblings," she explained.
"Unified legislation is required to set up central donor registries for each country and enforce limits around the number of donor-conceived people born from one donor to reduce the risk of consanguineous relationships and the psychological impact of discovering an unlimited number of potential siblings.
"Proper record keeping would allow central donor registries to share information with each other and ensure those seeking and providing donor conception can operate in a more regulated, safer environment."
Associate Professor Goedeke is from the Department of Psychology and Neuroscience at the Auckland University of Technology, and she is the Co-Chair of the ASPIRE Special Interest Group on Psychology and Counselling.
She said unregulated donor conception raised potential legal issues surrounding parentage, access rights to offspring and responsibilities for financial child support.
"Significant advances in science that have allowed families to be created using donated gametes have also advanced the growing availability of direct-to-consumer DNA testing," Associate Professor Goedeke explained. "This, coupled with a growing recognition of the rights and needs of donor-conceived people has driven a shift toward greater openness.
"DNA testing has become commonplace among people who suspect they were donor conceived and so true donor anonymity is no longer guaranteed. DNA samples may allow the tracing of anonymous donors and donor conceived people and access to medical and genetic data.
"Donor conceived people have the right to develop and conserve mutually agreeable relationships with biological, social and gestational families regardless of when or where they were born.
"But DNA testing for biological links can also have its downsides. In an unsupported environment, it can be challenging to negotiate outreach to individuals who may be previously unknown genetic relatives. Individuals to whom they outreach may not be anticipating contact, or genetic siblings may not be aware of their own donor conception, so responses may become psychologically confronting.
"Donor conception is a growing trend that is becoming more complex, so guidance is needed to help the recipients/parents, donors and donor conceived people to navigate the rapidly changing landscape in assisted reproduction. Donor conception is not just a treatment to help individuals conceive. It is a form of family building with long-term implications for all involved."
Associate Professor Goedeke said donor registries, donor limits, support for parents to disclose and access to properly recorded information were required to ensure ethical donor conception. This includes an understanding of complex cultural and religious contexts.
"Policy makers and health care professionals have a duty to ensure that adequate support provisions are in place to promote the health and well-being of all parties affected by donor conception," she said. "Qualified counsellors in clinical settings can provide psychosocial and decision-making support, education and advocacy and, if sought, help manage linking between donors, parents, children and siblings."
More than 2,000 experts in fertility health are attending the ASPIRE Congress at the Suntec Convention and Exhibition Centre in Singapore. For more information, go to www.aspire2025.com
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Korea Herald
19 hours ago
- Korea Herald
HTL Biotechnology inaugurates a new production line dedicated to sterile hyaluronic acid
JAVENÉ, France, June 6, 2025 /PRNewswire/ -- On the occasion of National Bioproduction and Biomedicines Day (JNBB), which enjoys the high patronage of the President of the French Republic, HTL Biotechnology confirms its position as a globalleader in the development and production of pharmaceutical-grade biopolymers, by inaugurating a new production unit dedicated to sterile hyaluronic acid at its Javené (Ille-et-Vilaine) site, a true flagship of French biomanufacturing. With over 30 years of expertise in biopolymers, HTL Biotechnology is reaffirming its commitment through this new production unit to the development of innovative therapeutic solutions for the medicine of today and tomorrow. The manufacture of sterile hyaluronic acid opens the way to new therapeutic opportunites . This cutting-edge process now makes it possible to combine hyaluronic acid with heat-sensitive active molecules, previously incompatible with traditional heat sterilization methods. Simultaneously, mastery of aseptic processes eliminates any risk of microbial contamination and ensures optimum pharmaceutical quality. This innovation marks a decisive step in the development of new combined formulations, bringing improved clinical benefits for patients in many fields, such as ophthalmology and drug delivery. This €12 million investment, part of HTL Biotechnology's €100 million 2022-2026 strategic plan, pursues two main goals: to explore new opportunities in bioproduction, and to strengthen the company's position as a key player in future applications of hyaluronic acid in healthcare. Production is scheduled to start in 2026, following qualification and validation of the industrial equipment. To guarantee the quality and efficiency of this new production unit, HTL Biotechnology has set up specific in-house training courses to instruct its staff in aseptic procedures and the handling of this new product. Because of the highly technical nature of this product, a team of ten specialists has been trained in the specific skills required for its production ensuring the highest quality standards. François Fournier, CEO of HTL Biotechnology, states: " I'm delighted with the prospects this investment gives us for further innovation in pharmaceutical-grade biopolymers. The breadth and complementarity of our portfolio is unique, and we are proud to be able to serve our customers even better. Thanks to this new unit, promising future applications can be explored, offering innovative solutions for the benefit of patients. I am delighted to be able to count on this new facility, which makes our historic Javené site a true flagship for French bioproduction." As an active member of France Biolead, HTL Biotechnology is proud to take part in the second National Biomanufacturing and Biomedicines Day, which this year enjoys the patronage of French President Emmanuel Macron. The company welcomes this recognition, which underscores the strategic importance of the French biomanufacturing and biomedical industry, at the heart of the challenges facing public health, and France. About HTL HTL Biotechnology is a French biotech company and world leader in the development and responsible biomanufacturing of pharmaceutical-grade biopolymers (Hyaluronic Acid, Polynucleotides and soon recombinant human collagen). These biopolymers are used by healthcare companies to develop treatments in a variety of leading therapeutic areas such as ophthalmology, dermatology, medical aesthetics and rheumatology. HTL Biotechnology recently strengthened its position as world leader in the development of pharmaceutical-grade biopolymers by acquiring, through its subsidiary HTL Biotechnology Innovation Inc. (HTL BII - New Jersey), a recombinant protein platform whose most advanced product is recombinant human collagen type III (rhCOL3) at a world-class scientific research center. To meet the world's growing need for biopolymers, the company also has subsidiaries in Asia and is building a neuromodulator production unit in the United States (HTL BMI - Massachusetts). Historically based in Javené (Brittany - France), the company brings together production, innovation, R&D , as well as quality activities on its site. HTL Biotechnology employs nearly 300 people worldwide. Press contact


Korea Herald
a day ago
- Korea Herald
Biotropics Malaysia Berhad Signs Strategic MOU with ASK Intercity Co., Ltd. to Bring Physta® Tongkat Ali to the Japanese Market
KUALA LUMPUR, June 6, 2025 /PRNewswire/ -- In a significant move to advance natural, evidence-based health solutions in Japan, Biotropics Malaysia Berhad has signed a Memorandum of Understanding (MOU) with ASK Intercity Co., Ltd. for the sales and distribution of Physta ® Tongkat Ali, Biotropics' proprietary standardized extract, in the Japanese market. The MOU signing took place at the Malaysian Pavillion of the World Expo Osaka 2025, during the opening of 'Sustainable Agriculture Week' witnessed by The Honorable Datuk Seri Haji Mohamad bin Sabu, Minister of Agriculture and Food Security. This partnership unites two companies with a shared commitment to the development and marketing of high-quality, clinically supported herbal ingredients. With decades of industry experience, both companies are dedicated to raising the standards of natural product innovation through scientific rigor, transparency and product integrity. Physta ® Tongkat Ali, developed through a landmark collaboration between the Malaysian Government and the Massachusetts Institute of Technology (MIT), stands as one of the world's most clinically studied Tongkat Ali (Eurycoma longifolia) extracts. It is backed by over 20 clinical studies and has been shown to support energy, vitality, libido, immunity, stress management and hormonal health. Recently, new research from Biotropics has uncovered Physta ® 's efficacy in supporting hormonal balance and reducing stress in pre- and postmenopausal women—a breakthrough expansion from its earlier positioning as a male-centric supplement. This positions Physta ® as a versatile ingredient for a broader demographic, supporting both men and women in managing age-related health challenges naturally. "In light of Japan's rapidly ageing population and growing demand for preventive, plant-based health solutions, we believe Physta ® brings timely and relevant benefits," said Haliza Ramli, CEO of Biotropics Malaysia. "There is a surge of interest for Tongkat Ali globally and this collaboration reflects a mutual vision: to deliver clinically supported, high-quality herbal ingredients that meet the needs of discerning, health-conscious consumers." Koichi Hosaka, CEO and Managing Director of ASK Intercity, added, "We are excited to work with Biotropics, a globally respected leader in herbal research. Tongkat Ali is already recognized internationally, and we believe Physta ® will be very appealing to Japanese consumers seeking natural vitality, stress support, hormonal balance and even looking for Power of Malaysian original forest". The partnership arrives at a pivotal time: Japan has the world's oldest population, with over 29% aged 65 and above. As healthy ageing becomes a national priority, ingredients like Physta ® —with proven benefits and gender-inclusive applications—offer real value to brand owners formulating for this dynamic segment. The MOU aims to redefine natural wellness in one of Asia's most mature and discerning health markets and sets foundation for future cooperation between Malaysia and Japan in the field of herbal science, innovation and market development. Biotropics' portfolio—including BioKesum ®, SLP+ ®, Nu-Femme ®, and Eurecta ® —continues to expand, driven by strong IP, clinical validation and Malaysia's rich botanical heritage.

Korea Herald
2 days ago
- Korea Herald
FutureCeuticals, Inc. Announces Peer-Reviewed Publication Highlighting Cellular Health and Immune Support Benefits of vitAlign®
MOMENCE, Ill., June 5, 2025 /PRNewswire/ -- New research published in the International Journal of Molecular Sciences shows that vitAlign®, a proprietary and comprehensive healthy aging innovation from FutureCeuticals, delivers significant benefits for restoring cellular health and supporting a healthy immune response. The study highlights vitAlign's effectiveness in regulating cellular function and metabolic imbalances associated with immune stressors—from the seasonal cold and flu to more complex environmental and immune-related challenges. Researchers evaluated the impact of a low, 50 mg dose of vitAlign in medically stable adults aged 40–55 recovering from a moderate course of COVID-19, as defined by CDC guidelines. The study compared vitAlign to a 1000 mg dose of Vitamin C, focusing on key markers and processes that directly impact immune and cellular health. Results showed that vitAlign significantly reduced excessive reactive oxygen species (ROS) production in mitochondria and through the NOX2 and iNOS pathways—key mechanisms that influence immune and cellular function. Additionally, researchers observed increased levels of circulating, bioavailable nitric oxide, suggesting support for endothelial function and cardiovascular health. The authors noted that the increase in nitric oxide is likely attributable to vitAlign's ability to regulate multiple pathways of ROS production. Notably, vitAlign delivered measurable effects within 30 minutes, lasting up to three hours. In contrast, Vitamin C, which was used as a positive control, was administered at twenty times the dose and did not demonstrate comparable broad-spectrum activity. "These findings build on over a decade of published clinical research establishing vitAlign as a significant cellular health innovation, now extended directly to immune function," said J. Randal Wexler, FutureCeuticals' General Counsel and Vice President of R&D. "Previously, we've shown that vitAlign improves cellular energy efficiency and helps restore metabolic balance, both acutely and over time." Wexler added, "These new results, which compare favorably to a well-known antioxidant like Vitamin C, reinforce vitAlign's potential as a multi-faceted phytonutrient formula, providing broad support for healthy aging, cardiovascular health, and immune function. Our partners are excited about what this means for product innovation and their customers looking for daily cellular health support." About FutureCeuticals: FutureCeuticals, Inc. is the developer of vitAlign and a leader in the research, development, and manufacture of plant-based powders and extracts for the functional food, beverage, and dietary supplement markets.